Tradestie Institutional Equity Comparison Engine
COCP vs ENTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ENTX Overall Edge
ENTX Captures Institutional Edge (3โ0 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, COCP trades at N/M Forward P/E with -3063.6% operating margin (+26.9% YoY revenue) versus ENTX at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ENTX sits in CONSOLIDATION (32nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
COCP N/M vs ENTX N/M Fwd P/E
Growth & Margin Winner
ENTX
Op Margin -3063.6% vs 0.0% ยท YoY +26.9% vs -100.0%
Momentum & Technical Winner
ENTX
1Y -1.5% vs +11.1% ยท 52W Pos 20% vs 64%
Options & Structure Winner
ENTX
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (32nd %ile IV)
COCP
NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.01
+3.82% 1D
Market Cap
$18.9M
1M Return
+7.23%
1Y Return
-1.46%
Forward P/E
N/M
Unified AI Score
38.7 / 100
SELL
Tech 25.0
Fund 43.0
Flow 50.0
Mom 54.0
ENTX
NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.01
-0.33% 1D
Market Cap
$541.6M
1M Return
+2.38%
1Y Return
+11.07%
Forward P/E
N/M
Unified AI Score
53.5 / 100
HOLD
Tech 35.0
Fund 55.0
Flow 72.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
COCP -1.46%
ENTX +11.07%
Spread: +12.53 pp (ENTX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | COCP Revenue | ENTX Revenue | COCP Op. Margin | ENTX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2011 | $10M | N/A | -30.6% | N/A | COCP |
| FY2019 | $10M | N/A | -737.4% | N/A | COCP |
| FY2020 | $0M | $0M | -476.0% | -3059.7% | COCP |
| FY2021 | N/A | $0M | N/A | -2139.6% | ENTX |
| FY2022 | N/A | $0M | N/A | -9714.2% | ENTX |
| FY2024 | N/A | $0M | N/A | -5295.6% | ENTX |
| FY2025 | N/A | $0M | N/A | -27450.0% | ENTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | COCP | ENTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $18.9M | $541.6M | Larger Scale | ENTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +26.9% | -100.0% | Higher Growth | COCP |
| Operating Margin (TTM) Profitability | -3063.6% | 0.0% | Higher Margin | ENTX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -311.7% | -20.3% | Higher ROE | ENTX |
| 52-Week Range Position Momentum | 20% ($1โ$2) | 64% ($1โ$4) | Stronger Trend | ENTX |
| Beta / 30D Volatility Risk Regime | 0.97ฮฒ ยท 55% Vol | 1.07ฮฒ ยท 45% Vol | Lower Realized Risk | ENTX |
| Unified Institutional Score Composite Signal | 38.7 / 100 (SELL) | 53.5 / 100 (HOLD) | Higher Composite | ENTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full COCP vs ENTX Buy Guide
COCP
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ENTX
CONSOLIDATION
80d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
32nd %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither COCP nor ENTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.